A recent study found that dermatology patients taking long-term steroids are not always evaluated for steroid-induced osteoporosis…
Search results for: corticosteroids
Why Oral Corticosteroids Should Not be Used in Patients with Rheumatoid Arthritis
Steroid use in patients with rheumatoid arthritis (RA) has been linked to higher mortality rates, greater rate of infections, more cases of pneumonia, and serious gastrointestinal events
Can Cultural Humility Conquer Systemic Inequity in Pediatric Rheumatology?
Doctors and patient advocates urged the rheumatology community to address the drastic inadequacies in care faced by marginalized people in a session held at ACR Convergence 2024.
Rheumatic Manifestations of Diabetes (Mimics, Common Culprits & More)
Understanding the intersection of diabetes mellitus & rheumatic diseases, including lesser known rheumatic entities of diabetes, such as diabetic cheiroarthropathy, scleredema & diabetic myonecrosis, is crucial for accurate diagnosis.
Type I IFNs in Cutaneous Lupus & Dermatomyositis
Type I interferons (IFNs) play an important role in the immunopathogenesis of cutaneous lupus erythematosus and dermatomyositis skin inflammation, which could potentially be treated with IFN-targeted therapies.
Lupus Update: Findings from the Latest Phase 3 Clinical Trials
Two new treatment studies among patients with systemic lupus erythematosus and lupus nephritis had promising results.
Making Sense of Autoimmune Sensorineural Hearing Loss
An unusual autoimmune inner ear condition results in hearing loss, but is reversible if treated.
The Rheumatologist’s Role in Sarcoidosis
Rheumatologists are uniquely positioned to care for patients with sarcoidosis. Here are insights into the condition, its treatment and more.
Helping Patients with SLE Thrive
Dr. Laurent Arnaud highlighted the latest information on systemic lupus erythematosus (SLE), including genetics, technology, treat to target, and promising findings for pulse therapy in his session at EULAR 2024.
FDA Approves Sarilumab for pJIA
The FDA has granted sarilumab its first pediatric indication, approving the agent to treat active, polyarticular juvenile idiopathic arthritis (pJIA) in patients who weigh at least 63 kgs.
- 1
- 2
- 3
- …
- 42
- Next Page »